Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100120 | 0.79 | CYP3A4 (0.36) | DGAT1 | |
| SCHEMBL99015 | 0.78 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL18975759 | 0.76 | TPH1 (0.33) | DGAT1 | |
| SCHEMBL29710434 | 0.76 | TPH1 (0.41) | DGAT1 | |
| SCHEMBL30446012 | 0.76 | TPH1 (0.41) | DGAT1 | |
| SCHEMBL30445095 | 0.75 | SIGMAR1 (0.38) | DGAT1 | |
| SCHEMBL30445481 | 0.75 | SIGMAR1 (0.36) | DGAT1 | |
| SCHEMBL100799 | 0.75 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL99142 | 0.74 | SIGMAR1 (0.40) | DGAT1 | |
| SCHEMBL31089960 | 0.74 | SIGMAR1 (0.40) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | DGAT1 4526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.